[Paper publication]

“A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors”
(Cho et al. 2021. J Thorac Oncol. S1556-0864(21)03403-1)

[Paper publication]

"Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies"
(Jang et al., 2021. JTO Clin Res Rep. 2(10): 100224)

[Paper publication]

"Lazertinib: First Approval"
(Dhillon S. 2021. Drugs. 81:1107-1113)

[Paper publication]

"EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation"
(Park et al., 2020. Cancer Res Treat. 52(4):1288-1290)

[Paper publication]

"YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-small cell lung cancer"
(Yun et al., 2019. Clin Cancer Res. 25(8):2575-2587)

[Paper publication]

"Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study"
(Ahn et al., 2019. Lancet Oncol. 20(12):1681-1690)

[Conference presentation]

“Effects of Food and Race on Pharmacokinetics of Lazertinib in Healthy Volunteers and Patients with EGFR Mutation Positive Advanced Non-small Cell Lung Cancer”
Poster (2021 AAPS)

[Conference presentation]

“Efficacy and Safety of Lazertinib 240 mg in Patients with EGFR T790M Mutant NSCLC: Data from a Phase I/II Study”
Poster (2021 Korean Association for Lung Cancer International Conference)

[Conference presentation]

"Cardiac Safety Assessment of Lazertinib in Patients With EGFR Mutation-positive Advanced Non-small Cell Lung Cancer"
Oral presentation (2020 WCLC)

[Conference presentation]

"ctDNA Resistance Landscape of Lazertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor (TKI)"
Poster (2020 ASCO)

[Conference presentation]

"Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC : Data from a phase I/II study"
Poster (2020 ASCO)

[Conference presentation]

"Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study"
Poster (2020 ASCO)

[Conference presentation]

"Lazertinib, a 3rd Generation EGFR‐TKI, in Patients with EGFR‐TKI resistant NSCLC: Updated Results of Phase I/II Study"
Poster (2019 ASCO)

[Conference presentation]

"Lazertinib, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI resistant NSCLC: Updated Results of Phase I/II Study"
Oral presentation (2019 KSMO)
New KSMO website under construction

[Conference presentation]

"Lazertinib, a Third Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Updated Results of a Phase I/II Study"
Oral presentation (2018 WCLC)

[Conference presentation]

"YH25448, an irreversible 3rd-generation EGFR TKI, exhibits superior anticancer effects with potent brain BBB penetration in NSCLC"
Poster (2018 AACR)

[Conference presentation]

"YH25448, a 3rd Generation EGFR‐TKI, in Patients with EGFR‐TKI‐resistant NSCLC: Phase I/II Study Results"
Poster (2018 ASCO)

[Conference presentation]

"YH25448, a highly selective 3rd generation EGFR TKI, exhibits superior survival benefit over osimertinib in mice with brain metastases of NSCLC"
Poster (2016 WCLC)